While Leqembi has shown promise in slowing the progression of Alzheimer’s disease, there are a number of tests required prior to the approval of treatment. Keta Medical Center will work with your neurologist to arrange for these tests prior to beginning treatment. These tests include: Medical Assessment: Conducted by your primary care provider or neurologist, this determines if you have mild cognitive impairment or mild Alzheimer’s Disease. MRI: This scan of your brain will reveal if there are other causes of MCI. Bloodwork: This will rule out other causes of cognitive impairments. Genetic Testing: Genetic testing, completed using a sample of blood or saliva, assesses if you have a gene called APOE. The presence of this gene is associated with a greater susceptibility to the risks of treatment, which include micro-hemorrhages and edema in the brain. A test for the presence of beta-amyloid in the brain: This can be a Positron Emission Tomography (PET) scan or a spinal fluid sample obtained using a lumbar puncture.